Boltz Raises $110 Million to Scale AI Drug Design
Bessemer-led Series A will fund headcount and computing infrastructure for Boltz's molecule and protein design models.
Updated on Nov. 19, 2026 in Startups

Live Poll
Do you think AI will make new medicines faster and cheaper for ordinary people?
Boltz PBC, which develops artificial intelligence models for pharmaceutical researchers, raised $110 million in Series A funding led by Bessemer. The round also included Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, and Hummingbird.
Why it matters
Drug discovery projects often review hundreds of thousands of candidate molecules and can take months and cost millions of dollars. Boltz's models aim to narrow that search, and its sales to six of the world's 20 largest pharmaceutical companies suggest demand from large drugmakers.
Boltz's $110 million Series A is its headline funding figure, and the company reports that customer token consumption has grown 50 times since BoltzMol-1 and BoltzProt-1 launched in June. The company has not disclosed independent verification of its claimed performance on the 10 targets tested.
The players
Boltz PBC
Boltz PBC is a company that develops artificial intelligence models used by pharmaceutical researchers in drug discovery.
Bessemer
Bessemer is a venture capital firm that led the Series A investment in Boltz.
The details
BoltzMol-1 can be configured to consider only small molecules that can be made from a limited set of available compounds, and BoltzProt-1 generates tens of thousands of protein designs from small molecule hit data. BoltzProt-1 automatically reviews each generated protein to determine whether it could be used to develop a new drug. Boltz sells its algorithms through an application programming interface billed by token usage.
Timeline
June: BoltzMol-1 and BoltzProt-1 launched.
Wednesday: Boltz announced the $110 million funding round.
The Big Picture
Boltz builds on the protein modeling advances popularized by AlphaFold, shifting from predicting protein structures toward generating candidate designs for drugs. Its move into design places it among startups aiming to automate earlier stages of drug discovery.
For pharmaceutical teams, Boltz's usage-based API pricing means costs scale with how much a team runs the models rather than with a fixed license. Teams weighing these tools can compare token-based billing against their expected number of design runs.
The takeaway
Teams evaluating AI for drug discovery should test whether a model's claimed hit rates hold up on their own targets before committing budget. Usage-based pricing makes it cheap to run pilots that compare results against current screening methods.
Further reading
Explore more startup funding and company launches on Wisevoter.
Live Poll
Do you think AI will make new medicines faster and cheaper for ordinary people?



